By the first quarter 2022, 57% of US adults with type 2 diabetes taking an incretin-based agent were taking a GLP-1 receptor agonist; DPP-4 inhibitor use fell to 39% of these scripts.
Low co-pays linked with substantially better 12-month adherence to expensive SGLT2 inhibitors and GLP-1 agonists among US patients with type 2 diabetes or heart failure.
Among more than 80,000 older adults with T2D and established CVD, those in the highest quartile of out-of-pocket costs were less likely to initiate a GLP-1 R or SGLT2 inhibitor.